This study was to explore the preventive effect of esketamine on postpartum depression (PPD) in cesarean section, and to evaluate the safety of the drug
Studies have shown that esketamine can treat clinical refractory depression, the drug takes effect quickly, can quickly eliminate the patient's suicide intention, low-dose maintenance treatment is conducive to the stability of the patient's condition, and less adverse reactions, is the current hot spot of antidepressant drug research. Esketamine has been approved by FDA for the treatment of refractory and suicidal depression, but can it effectively prevent and treat postpartum depression? It is not clear. Based on this, this study aims to explore the preventive effect of prophylactic administration of esketamine on postpartum depression in cesarean section, and evaluate the safety of the drug.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
336
After delivery, the parturient was given a loading dose of esketamine, and then a small dose of esketamine was added into PCIA analgesia pump
10 ml normal saline
Tongji Hospital
Wuhan, Hubei, China
Edinburgh Postnatal Depression Scale(EPDS） scores
EPDS score is 0-30，and ≥ 10 to indicate depression
Time frame: up to 90 days after surgery
Numeric Rating Scale (NRS) score
NRS score is 0-10，and ≥ 4 to indicate the pain needs treatment
Time frame: 1 Day before operation
total number of patient-controlled analgesia (PCA) compressions
the total number of PCA compressions which the patients pressed
Time frame: up to 24 hours after operation
total volume of PCA
the total volume of PCA drugs which the patients needed in 24h after surgery
Time frame: up to 24 hours after operation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.